After we employed the same algorithm on patients with glioblastomas after anti-PD1 treatment using pembrolizumab, which is a humanized monoclonal immunoglobulin G4 (IgG4) anti-PD1 antibody, we found that the functions of DEGs between post-treatment and pre-treatment, the enrichment of pathways related to tumor progression, and clinical responses to anti-PD1 treatment were considerably different, suggesting that immune-related patient stratification could be a latent biomarker of reaction and clinical response to the PD-1 blockade in glioblastomas. The gene discussed is PDCD1; the disease is neoplasm.